Tuesday, November 24, 2009, 8:23pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

ARYx Therapeutics, Inc. (ARYX)

At 5:00AM SGT: 2.47 USD   0.00 (0.00%)  
 MORE ON ARYX 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 ARYx Therapeutics, Inc. (NGM:ARYX) Delayed quote dataEdit
Last Trade:2.47 USD
Trade Time:5:00AM SGT
Change: 0.00 (0.00%)
Prev Close:2.47
Open:N/A
Bid:N/A
Ask:N/A
1y Target Est:6.38
Day's Range:N/A - N/A
52wk Range:1.30 - 6.32
Volume:0
Avg Vol (3m):76,070.8
Market Cap:68.14M
P/E (ttm):N/A
EPS (ttm):-1.54
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y 
Use Y! Toolbar to track stocks
 Add ARYX to Portfolio   Download Data

 HEADLINES 
•ARYX THERAPEUTICS, INC. Financials
EDGAR Online Financials (Wed, Nov 18)
•Results From Phase 2b Study on Atrial Fibrillation Agent Reviewed at American Heart Association
Business Wire (Wed, Nov 18)
•New Star Analyst Rankings for ARYx Therapeutics, Inc.
StarMine (Sun, Nov 15)
•ARYX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
EDGAR Online (Fri, Nov 13)
•Aryx Therapeutics reports $8.2M loss
at bizjournals.com (Fri, Nov 13)
•Third Quarter 2009 Results and Earnings Call scheduled for 11:00 am ET today
Shareholder.com (Fri, Nov 13)
•ARYx Therapeutics Reports Third Quarter 2009 Results
Business Wire (Thu, Nov 12)
•Q3 2009 ARYx Therapeutics Earnings Release - Time Not Supplied
CCBN (Thu, Nov 12)
•ARYX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
EDGAR Online (Thu, Nov 12)
•ARYx Therapeutics Schedules Third Quarter 2009 Results Conference Call
Business Wire (Thu, Nov 5)
More Headlines for ARYX...
 ANALYST 
EPS Est (next year) (Dec-09) :-1.11
EPS Est (in 2 years) (Dec-10) :-0.27
Avg Rec (current)*:1.3
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of product candidates designed to eliminate known safety issues associated with commercial drugs using its RetroMetabolic Drug Design technology.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices